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Abstract
Background: Controversies were previously observed with the concomitant use of clopidogrel and Proton Pump
Inhibitors (PPIs), especially omeprazole, following coronary angioplasty. Even though several studies showed no
interaction between clopidogrel and PPIs, questions have been raised about the decrease in antiplatelet effects of
clopidogrel with PPIs. A previously published meta-analysis showed concomitant use of clopidogrel and PPIs to be
associated with higher adverse cardiovascular outcomes. However, data which were used were extracted from studies
published before the year 2012. Whether these controversies still exist in this new era is not clear. Therefore, we aim to
show if the concomitant use of clopidogrel and PPIs is still associated with higher adverse outcomes following
Percutaneous Coronary Intervention (PCI) using data obtained from recently published studies (2012 to 2016).
Methods: Electronic databases were searched for recent publications (2012–2016) comparing (clopidogrel plus PPIs)
versus clopidogrel alone following PCI. Adverse cardiovascular outcomes were considered as the clinical endpoints.
Odds Ratios (OR) with 95% Confidence Intervals (CI) were used as the statistical parameters and the pooled analyses
were performed with RevMan 5.3 software.
Results: Eleven studies with a total number of 84,729 patients (29,235 patients from the PPIs group versus 55,494
patients from the non-PPIs group) were included. Results of this analysis showed that short term mortality and Target
Vessel Revascularization (TVR) significantly favored the non-PPIs group with OR: 1.55; 95% CI: 1.43–1.68, P < 0.00001 and
OR: 1.26; 95% CI: 1.06–1.49, P = 0.009 respectively. Long-term Major Adverse Cardiac Events (MACEs), Myocardial
Infarction (MI), Stent Thrombosis (ST) and TVR significantly favored patients who did not use PPIs with OR: 1.37; 95% CI:
1.23–1.53, P < 0.00001, OR: 1.41; 95% CI: 1.26–1.57, P < 0.00001 and OR: 1.38; 95% CI: 1.13–1.70, P = 0.002 and OR: 1.28;
95% CI: 1.01–1.61, P = 0.04 respectively. However, the result for long term mortality was not statistically significant.
Conclusion: The combined use of clopidogrel with PPIs is still associated with significantly higher adverse cardiovascular
events such as MACEs, ST and MI following PCI supporting results of the previously published meta-analysis. However,
long-term mortality is not statistically significant warranting further analysis with randomized patients.
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Background
Controversies still exist with the concomitant use of
clopidogrel, one of the components of the Dual Anti-
Platelet Therapy (DAPT) with Proton Pump Inhibitors
(PPIs), especially omeprazole following Percutaneous
Coronary Intervention (PCI). Even if the American
College of Cardiology/Gastroenterology and the American
Heart Association recommend prophylactic treatment
with a PPI in those patients who require DAPT and those
patients who are at high risk of gastrointestinal injury [1],
recent studies have shown clopidogrel and PPIs to be me-
tabolized by the same cytochrome P450 2C19 (CYP2C19)
pathway [2].
Several studies showed no interaction between clopi-
dogrel and PPIs. For example, Rassen et al. showed a
slight increase in the rate of Myocardial Infarction (MI)
and mortality in older patients discharged on clopidogrel
and PPIs, but the authors were not able to conclude any
interaction between PPIs and clopidogrel in terms of
major clinical relevance [3]. Zairis et al. also showed no
impact of omeprazole on the clinical efficacy of clopido-
grel during the first year following PCI [4].
However, decrease in antiplatelet effects of clopidogrel
with the concomitant use of PPIs has been observed.
Patients had a higher level of platelet reactivity which re-
sulted in an increased risk of adverse clinical outcomes
[5]. For example, Gupta et al. concluded that the con-
comitant use of clopidogrel with PPIs following coronary
stents implantation was associated with a significantly
higher risk of major adverse cardiac events (MACEs) [6].
In 2012, Huang et al. conducted a meta-analysis based
on the current idea, using old data (2009–2011) [7]. Re-
sults from their meta-analysis showed significantly in-
creased risk of MACEs in patients with the concomitant
use of clopidogrel and PPIs. Unfortunately, the high level
of heterogeneity observed among the different sub-
groups analyzed was their major limitation.
Recently, many new studies were published based on
the cardiovascular outcomes observed in patients treated
with clopidogrel plus PPIs and clopidogrel alone following
PCI. However, whether these controversies still exist in
this new era is not clear. Therefore, we aim to show if the
concomitant use of clopidogrel and PPIs is still associated
with higher adverse outcomes following PCI using data
obtained from recently published studies (2012 to 2016).
Methods
Data sources and search strategy
Three reviewers (P.K.B, A.R.T and A.B) carefully
searched EMBASE, PubMed/Medline databases, and the
Cochrane library for Randomized Controlled Trials
(RCTs) and observational studies comparing the con-
comitant use clopidogrel with PPI and clopidogrel alone
following PCI. The terms ‘proton pump inhibitor and
clopidogrel’, ‘proton pump inhibitor and percutaneous
coronary intervention’ and ‘proton pump inhibitor and
dual antiplatelet therapy’ were searched carefully. In
addition, abbreviations such as PPI, PCI and DAPT were
also used. In order to widen the search process, individ-
ual PPIs namely ‘omeprazole, pantoprazole, lansoprazole,
esomeprazole, and rabeprazole’ were also used in this
search strategy. Because this current meta-analysis was
based on recently published English articles, and since the
previously published meta-analysis already included old
data published before or in the year 2011, only studies
published after the year 2011 (2012 to 2016) were consid-
ered relevant. Unpublished data were not included.
Inclusion and exclusion criteria
RCTs and observational studies were included if:
(a)They compared patients treated with (clopidogrel
and PPIs) and patients treated with clopidogrel but
without PPIs following coronary stenting.
(b)Adverse cardiovascular outcomes were reported as
their clinical endpoints.
(c)They were published after the year 2011.
RCTs and observational studies were excluded if:
(a)They did not compare patients (clopidogrel and PPIs)
with clopidogrel alone following coronary stenting.
(b)Adverse cardiovascular outcomes were not reported
as their clinical endpoints.
(c)They were published before or in the year 2011.
(d)They were duplicates.
Outcomes and follow up periods




(c)Target vessel revascularization (TVR)
(d)Stent thrombosis (ST)
(e)MACEs which consisted of death, MI and repeated
revascularization.
Follow up period was divided into a short term follow up
period (<1 year) and a long term follow up period (≥ 1 year).
Data extraction and quality assessment
Three authors (P.K.B, A.R.T and A.B) independently
reviewed the data extracted from the studies included in
this meta-analysis. Information regarding the type of
study, the total number of patients in the study group
and the control group respectively, data regarding the
baseline characteristics of the patients involved,
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information regarding the cardiovascular outcomes re-
ported as well as the follow up periods associated
with each eligible study were systematically extracted.
At a certain point, when the authors disagreed about
including certain studies, disagreements were resolved
and a final decision was made by the fourth author
(W.Q.H). Since only two trials were included in this
meta-analysis whereas the other studies were observa-
tional cohorts, the risk of bias was not assessed [8].
Methodological quality and statistical analysis
Recommendations from the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses guideline
were followed [9]. Heterogeneity was assessed using the
following:
(a)Cochrane Q-statistic test based on a P value with a
cut-off point of 0.05 whereby a value less or equal to
0.05 was considered statistically significant.
(b)I2-statistic test whereby an increasing value denoted
an increasing heterogeneity.
A fixed effects model (I2 < 50%) or a random effects model
(I2 > 50%) was used based on the value of I2 obtained.
Odds Ratios (OR) with 95% Confidence Intervals (CIs)
were calculated. The pooled analyses were performed
with RevMan 5.3 software.
Publication bias was assessed by observing funnel
plots. The reason for using funnel plots was the fact that
studies with a smaller volume were used. For studies of
smaller volumes, due to the higher degree of random
changes, they have a wider distribution of results com-
pared to studies of greater volumes. This might cause
asymmetry in the funnels whereby publication bias could
therefore be visually estimated.




A total number of 1153 articles were obtained from the
searched databases. One thousand and ninety-six articles
were rejected since they were either not related to this
current topic or they were duplicates. Fifty-seven full
text articles were assessed for eligibility. A further six ar-
ticles were eliminated since they were case studies and
meta-analyses. Three more articles were eliminated be-
cause their data could not be used (outcomes were re-
ported in terms of Hazard Ratio which was not
appropriate to be used in meta-analysis). In addition, 37
more articles were eliminated since they were published
before the year 2012. Finally, 11 articles were included in
this analysis (Fig. 1).
Baseline characteristics
A total number of 84,729 patients were included in this
analysis (29,235 patients treated with clopidogrel plus
PPIs and 55,494 patients treated with clopidogrel alone).
The general features of the studies have been summa-
rized in Table 2.
Study Douglas 2012, which was conducted in United
Kingdom, consisted of the highest number of patients,
followed by the studies Bhurke 2012, Dunn 2013 and
Goodman 2012 respectively.
The baseline features of the patients have been listed
in Tables 3 and 4 lists the different types of PPIs used by
the patients.
According to the baseline features, there was no sig-
nificant difference among the patients who were treated
with (clopidogrel plus PPIs) and clopidogrel alone.
Main results of this meta-analysis
Results of this analysis (summarized in Table 5) showed
that during a short term follow up period, using a fixed
effects model, mortality and TVR significantly favored
Table 1 Reported outcomes and their follow up periods
Study Reported outcomes Follow up periods Type of follow up
Bhurke 2012 [17] MI and revascularization 9 months Short term
Burkard 2012 [18] Death, MI, ST, MACE, TVR 3 years Long term
Chitose 2012 [19] Death, MI 18 months Long term
Douglas 2012 [20] Death, MI 10 months Short term
Dunn 2013 [21] Death, MI, TVR 1 month Short term
Goodman 2012 [22] Death, MI, ST 1 year Long term
Hsieh 2015 [23] MI, revascularization 1 year Long term
Macaione 2012 [24] Death, MI, TVR 3 years Long term
Weisz 2015 [25] Death, MACEs, MI, ST, TVR In hospital, 2 years Short and long term
Zou 2014 [26] Death, MACEs, MI, ST, TVR 1 year Long term
Gargiolo 2016 [16] Death, MACEs, MI, ST 2 years Long term
Abbreviations: MI Myocardial infarction, ST Stent thrombosis, MACEs Major adverse cardiac events, TVR Target vessel revascularization
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clopidogrel alone with OR: 1.55; 95% CI: 1.43–1.68, P <
0.00001 and OR: 1.26; 95% CI: 1.06–1.49, P = 0.009 re-
spectively. This result has been represented in Fig. 2.
However, result for the short-term MI which was ana-
lyzed using a random effects model, was not statistically
significant with OR: 1.17; 95% CI: 0.86–1.58, P = 0.32
(Fig. 3).
During the long-term follow up period, MACEs, MI
and ST significantly favored clopidogrel alone with OR:
1.37; 95% CI: 1.23–1.53, P < 0.00001, OR: 1.41; 95% CI:
Fig. 1 Flow diagram for the study selection
Table 2 General features of the studies included
Studies No of patients using
clopidogrel + PPIs (n)
No of patients using
clopidogrel alone (n)
Type of study Region
Bhurke 2012 2958 7143 Retrospective United states
Burkard 2012 109 692 Retrospective United states
Chitose 2012 187 443 Observational Japan
Douglas 2012 12439 16900 Observational United Kingdom
Dunn 2013 408 9191 Retrospective Charlottesville
Goodman 2012 3255 6021 RCT Canada
Hsieh 2015 670 5933 Observational Taiwan
Macaione 2012 121 55 Retrospective Italy
Weisz 2015 2162 6419 Observational Israel
Zou 2014 6188 1465 Observational China
Gargiolo 2016 738 1232 RCT Italy
Total no of patients (n) 29,235 55,494
Abbreviations: PPIs Proton pump inhibitor, RCT Randomized controlled trial
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1.26–1.57, P < 0.00001 and OR: 1.38; 95% CI: 1.13–1.70,
P = 0.002 respectively (Fig. 4).
However, since a high level of heterogeneity was ob-
served when analyzing the long-term mortality and
TVR, a random effects model was used. Long term TVR
also significantly favored the non-PPI group with OR:
1.28; 95% CI: 1.01–1.61, P = 0.04 whereas the result for
the long-term mortality was not statistically significant
with OR: 1.26; 95% CI: 0.99–1.60, P = 0.06 (Fig. 5).
Based on a visual inspection of the funnel plot, there
has been a low evidence of publication bias among the
studies that assessed several subgroups of adverse
cardiovascular endpoints. These funnel plots have been
illustrated in Fig. 6a and b.
Discussion
Controversies still exist with the concomitant use of
clopidogrel and PPIs following coronary stenting, which
remain to be solved in this new era. In this analysis, we
aimed to compare the adverse clinical outcomes associ-
ated with the concomitant use of clopidogrel and PPIs
versus clopidogrel alone following PCI using data ob-
tained from recently published articles (2012–2016).
This current analysis showed that during a short term
follow up period, mortality and revascularization were
significantly lower in those patients who did not require
treatment with PPIs. Moreover, during the long term fol-
low up period, adverse cardiovascular outcomes such as
MACEs, ST, MI and TVR significantly favored patients
in the non-PPI group. However, result for the long-term
mortality was similar manifested in both groups.
The previously published meta-analysis [7] which in-
cluded 32 studies with publication date before the year
2012 (29 studies published in English and 3 studies pub-
lished in Chinese), showed the concomitant use of PPI
and clopidogrel to be associated with higher MACEs
with OR: 1.27, 95% CI: 1.13–1.42 when a combination of
data obtained from randomized trials and observational
Table 3 Baseline characteristics of the patients
Study Age (year) Males (%) HT (%) Ds (%) DM (%) CS (%)
C + PPI/C alone C + PPI/C alone C + PPI/C alone C + PPI/C alone C + PPI/C alone C + PPI/C alone
Bhurke 2012 61.5/59.6 68.7/76.3 - - 28.9/26.4 -
Burkard 2012 66.5/63.3 68.8/79.9 72.5/65.0 73.4/75.9 29.6/17.2 24.8/29.8
Chitose 2012 70.3/68.9 71.6/72.2 77.9/79.0 61.9/61.7 35.3/33.7 23.9/26.2
Douglas 2012 71.0/68.0 58.0/65.0 - - 34.0/29.0 16.0/18.0
Dunn 2013 63.9/62.5 69.3/72.3 49.5/51.5 39.4/41.2 16.5/20.3 23.9/29.6
Goodman 2012 63.0/62.0 72.4/71.2 65.6/65.4 49.8/45.0 25.8/24.7 36.2/35.7
Hsieh 2015 68.4/66.5 63.6/66.4 - - - -
Macaione 2012 63.7/65.8 80.2/87.3 70.2/81.8 53.7/58.2 41.3/49.1 37.2/27.3
Weisz 2015 64.4/63.2 70.1/75.9 83.7/77.8 76.9/73.2 34.8/31.4 22.7/22.6
Zou 2014 66.2/65.7 73.5/73.9 71.3/70.4 60.2/62.3 25.8/23.6 32.2/31.0
Gargiolo 2016 71.2/68.1 72.5/79.2 72.5/71.3 53.8/55.3 23.3/24.8 22.6/24.4
Abbreviations: C Clopidogrel, PPI Proton pump inhibitor, HT Hypertension, Ds Dyslipidemia, DM Diabetes mellitus, CS Current smoker
Table 4 Types of Proton Pump Inhibitors used by the patients
Studies Omeprazole Esomeprazole Lansoprazole Pantoprazole Rabeprazole
Bhurke 2012 27.1 23.1 17.6 25.8 6.30
Burkard 2012 17.0 51.0 7.00 25.0 -
Chitose 2012 - - - - -
Douglas 2012 - - - - -
Dunn 2013 14.0 - 18.1 3.03 1.60
Goodman 2012 48.9 11.7 7.80 30.1 1.48
Hsieh 2015 - - - - -
Macaione 2012 43.0 11.6 10.7 34.7 -
Weisz 2015 - - - - -
Zou 2014 - - - - -
Gargiolo 2016 0.5 0.5 90.9 7.60 0.5
Percentage (%) has been used to represent these data
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studies was used. However, pooling data only from ran-
domized trials did not show any increase risk of MACEs
with OR: 0.92, 95% CI: 0.53–1.58; P = 0.72, I2 = 0%.
When mortality was analyzed using a random effects
model, a significant increase was observed with HR:
1.30, 95% CI: 0.91–1.86. But when a fixed effects model
was used to analyze mortality, no significant increase
was observed with clopidogrel plus PPI with OR: 0.92,
95% CI: 0.82–1.04.
Several reasons have been suggested for such a result.
First of all, PPIs involve the same metabolic pathway
(mainly CYP2C19 isoenzyme) with that of clopidogrel
[10]. In other words, by occupying the same metabolic
pathway as clopidogrel, PPIs are expected to reduce the
antiplatelet effects of clopidogrel. Because PPIs can act
as both, inhibitors and substrates of CYP2C19, patients
treated with clopidogrel and PPIs are vulnerable to a re-
duced effectiveness of clopidogrel. This could in turn re-
sult in a higher platelet activity following PCI finally
causing an increase in adverse clinical outcomes. Gilard
et al. were the first ones to show the interaction of
clopidogrel and PPIs [11]. Moreover, PPIs not only
showed a high platelet reactivity but also showed an in-
creased inflammatory state due to the rise in the level of
interleukins-6 which in turn could increase the occur-
rence of ischemic events [12]. However, whether PPIs
really have an effect on clopidogrel’s antiplatelet effect is
still being debated.
Similar to the results of this current analysis, many
other previously published studies showed that adverse
clinical outcomes were significantly increased in the PPIs
group. Gupta et al. concluded that the concomitant use
of clopidogrel with PPIs was associated with an in-
creased risk of MACEs following PCI [6]. In addition,
Ho et al. showed increased risk of adverse outcomes
with clopidogrel plus PPIs [13].
However, even if many studies supported these current
results, several other studies showed results which were
completely different. For example, Rassen et al. showed
that although a slight increase in hospitalization due to
MI and death was observed in older patients who were
prescribed PPIs and clopidogrel together, there was not
enough evidence to conclude any major interaction be-
tween these 2 drugs [3]. In the analysis from the Guthrie
Health Off-Label Stent (GHOST) Investigators, the
Table 5 Results of the main analysis
Outcomes analyzed OR with 95% CI P value I2 (%)
Short term follow up
Mortality 1.55 [1.43–1.68] 0.00001 0
TVR 1.26 [1.06–1.49] 0.009 22
MI 1.17 [0.86–1.58] 0.32 91
Long term follow up
MACEs 1.37 [1.23–1.53] 0.00001 0
MI 1.41 [1.26–1.57] 0.00001 29
ST 1.38 [1.13–1.70] 0.002 0
Mortality 1.26 [0.99–1.60] 0.06 61
TVR 1.28 [1.01–1.61] 0.04 72
Abbreviations: OR Odds ratio, CI Confidence interval, TVR Target vessel
revascularization, MI Myocardial infarction, MACEs Major adverse cardiac
events, ST Stent thrombosis
Fig. 2 Short term adverse clinical outcomes associated with the concomitant use of clopidogrel and PPIs
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Fig. 3 Short term Myocardial Infarction associated with the concomitant use of clopidogrel and PPIs
Fig. 4 Long term adverse clinical outcomes associated with the concomitant use of clopidogrel and PPIs
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authors also concluded that the use of PPIs with DAPT
was not associated with any increase in MACEs follow-
ing PCI [14]. However, their study had a follow up
period of only 6 months. Zairis et al. also showed no im-
pact of omeprazole on the clinical efficacy of clopidogrel
during the first year following successful PCI [4]. How-
ever, the authors concluded that further highly powered
studies should be conducted to confirm whether or not,
omeprazole has any effect on the antiplatelet mechanism
of clopidogrel. In addition, the COGENT study also did
not observe any apparent interaction between clopido-
grel and omeprazole, but however, the authors strictly
mentioned that their results did not rule out clinically
meaningful differences in adverse cardiovascular
outcomes due to the use of PPIs [15].
Nevertheless, among all the PPIs, omeprazole is
considered to have a higher effect on the mechanism of
clopidogrel. Other studies did not show any notable
inter-reaction among non-omeprazole PPIs and clopido-
grel. For example, when pantoprazole was used along
with clopidogrel, no increase in adverse events was
observed and therefore pantoprazole has been recom-
mended compared to omeprazole in patients treated
with clopidogrel. In addition, in a sub-analysis of the
randomized PRODIGY trial, it was reported that the
concomitant use of PPIs, when clinically indicated, in
patients receiving clopidogrel, was not associated with
adverse clinical outcomes. However, it should also be
noted that only less than 1.5% of the patients used
omeprazole while more than 90% of the patients in that
particular trial used lansoprazole, suggesting that this
type of PPIs might be safer to use with clopidogrel [16].
Since the adverse clinical events associated with non-
omeprazole PPIs and clopidogrel have still not clearly
been studied, further research is recommended with these
individual PPIs (esomeprazole, rabeprazole, lansoprazole,
and pantoprazole). In addition, bleeding events especially
gastrointestinal bleeding associated with the concomitant
use of clopidogrel with these individual PPIs should also
be carefully studied.
A moderate level of heterogeneity was observed
among certain subgroups analyzing the cardiovascular
outcomes. Only English publications were considered,
and articles written in other languages were ignored,
therefore, a language bias might most probably be
present. Moreover, data obtained from conference ab-
stracts and other unpublished studies were not in-
cluded. However, since most of the data used in this
analysis were obtained from observational studies, it
could be one of the reasons contributing to the mod-
erate risk of bias observed. In addition, a high level
of heterogeneity could also have been due to the fact
Fig. 5 Long term mortality and TVR associated with the concomitant use of clopidogrel and PPIs
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that different types of patients were included (chronic
stable angina, STEMI, NSTEMI) and the type of stent
following PCI was also not taken into consideration;
patients implanted with DES and BMS were com-
bined and analyzed.
Novelty in this study is the fact that a lower level of
heterogeneity was present among several subgroups
compared to the previously published meta-analysis.
Moreover, different from other studies which mainly re-
port either short term, mid-term or long term outcomes,
this analysis has compared the long term and short term
adverse clinical outcomes in patients with and without
the concomitant use of clopidogrel and PPIs. In addition,
this analysis included data obtained from newly pub-
lished research articles.
Limitations
Several limitations are present. Due to a limited number
of patients, the result of this analysis might be affected.
Moreover, this analysis involved mainly data obtained
from observational studies which might be another limi-
tation, and because of this reason, the bias risk of the
studies included in this analysis was not assessed using
recommendations from the Cochrane Collaboration. In
addition, one study reported death, MI and revasculari-
zation together. Since data for each outcome could not
a
b
Fig. 6 a and b Funnel plots showing publication bias
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be separated, we have included the same data for this
particular study in the different subgroups analyzing
mortality, MI and TVR. Also, adverse bleeding events
(GI bleeding) were not analyzed because only a few
studies reported bleeding outcomes, which were also dif-
ferent in each of the study, making it difficult to
compare.
Conclusion
The combined use of clopidogrel with PPIs is still associ-
ated with significantly higher adverse cardiovascular
events such as MACEs, ST and MI following PCI support-
ing results of the previously published meta-analysis.
However, long-term mortality is not statistically significant
warranting further analysis with randomized patients.
Abbreviations
DAPT: Dual antiplatelet therapy; MACEs: Major adverse cardiac events;
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